[1] Johnson DE, Burtness B, Leemans CR, et al.Head and neck squamous cell carcinoma[J]. Nat Rev Dis Primers, 2020, 6(1): 92-140. [2] Elmusrati A, Wang J, Wang CY.Tumor microenvironment and immune evasion in head and neck squamous cell carcinoma[J]. Int J Oral Sci, 2021, 13(1): 24-34. [3] Wang G, Zhang M, Cheng M, et al.Tumor microenvironment in head and neck squamous cell carcinoma: functions and regulatory mechanisms[J]. Cancer Lett, 2021, 507: 55-69. [4] Li B, Ren M, Zhou X, et al.Targeting tumor-associated macrophages in head and neck squamous cell carcinoma[J]. Oral Oncol, 2020, 106: 104723-104731. [5] Junttila MR, de Sauvage FJ. Influence of tumour micro-environment heterogeneity on therapeutic response[J]. Nature, 2013, 501(7467): 346-354. [6] Mhaidly R, Mechta-Grigoriou F.Fibroblast heterogeneity in tumor micro-environment: role in immunosuppression and new therapies[J]. Semin Immunol, 2020, 48: 101417-101429. [7] Kalluri R, Zeisberg M.Fibroblasts in cancer[J]. Nat Rev Cancer, 2006, 6(5): 392-401. [8] Nurmik M, Ullmann P, Rodriguez F, et al.In search of definitions: cancer-associated fibroblasts and their markers[J]. Int J Cancer, 2020, 146(4): 895-905. [9] Petitprez F, Meylan M, de Reyniès A, et al. The tumor microenvironment in the response to immune checkpoint blockade therapies[J]. Front Immunol, 2020, 11: 784-794. [10] Jochems C, Schlom J.Tumor-infiltrating immune cells and prognosis: the potential link between conventional cancer therapy and immunity[J]. Exp Biol Med (Maywood), 2011, 236(5): 567-579. [11] Kopp F, Mendell JT.Functional classification and experimental dissection of long noncoding RNAs[J]. Cell, 2018, 172(3): 393-407. [12] Wang KC, Chang HY.Molecular mechanisms of long noncoding RNAs[J]. Mol Cell, 2011,43(6): 904-914. [13] Zhou M, Zhang Z, Bao S, et al. Computational recognition of lncRNA signature of tumor-infiltrating B lymphocytes with potential implications in prognosis and immunotherapy of bladder cancer[J]. Brief Bioinform, 2021, 22(3): bbaa047-bbaa059. [14] Li R, Li F, Wang Y, et al. A three-long non-coding RNA signature that predicts tongue squamous cell carcinoma prognosis[J]. Oral Dis, 2021 Jul 28. [Online ahead of print]. [15] Seliger B, Massa C, Yang B, et al.Immune escape mechanisms and their clinical relevance in head and neck squamous cell carcinoma[J]. Int J Mol Sci, 2020, 21(19): 7032-7038. [16] Postepska-Igielska A, Giwojna A, Gasri-Plotnitsky L, et al.LncRNA Khps1 regulates expression of the proto-oncogene SPHK1 via triplex-mediated changes in chromatin structure[J]. Mol Cell, 2015, 60(4): 626-636. [17] Bridges MC, Daulagala AC, Kourtidis A.LNCcation: lncRNA localization and function[J]. J Cell Biol, 2021, 220(2): e202009045-e202009061. [18] Ali T, Grote P.Beyond the RNA-dependent function of LncRNA genes[J]. Elife, 2020, 9: e60583-e60596. [19] Yip CW, Sivaraman DM, Prabhu AV, et al.Functional annotation of lncRNA in high-throughput screening[J]. Essays Biochem, 2021, 65(4): 761-773. [20] Wang L, Cho KB, Li Y, et al.Long Noncoding RNA (lncRNA)-mediated competing endogenous RNA networks provide novel potential biomarkers and therapeutic targets for colorectal cancer[J]. Int J Mol Sci, 2019, 20(22): 5758-5783. [21] Fan CN, Ma L, Liu N.Systematic analysis of lncRNA-miRNA-mRNA competing endogenous RNA network identifies four-lncRNA signature as a prognostic biomarker for breast cancer[J]. J Transl Med, 2018, 16(1):264-275. [22] Wang H, Huo X, Yang XR, et al.STAT3-mediated upregulation of lncRNA HOXD-AS1 as a ceRNA facilitates liver cancer metastasis by regulating SOX4[J]. Mol Cancer, 2017, 16(1): 136-150. [23] Han C, Li H, Ma Z, et al.MIR99AHG is a noncoding tumor suppressor gene in lung adenocarcinoma[J]. Cell Death Dis, 2021, 12(5): 424-440. [24] Mao X, Xu J, Wang W, et al.Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives[J]. Mol Cancer, 2021, 20(1):131-160. [25] Fang Z, Meng Q, Xu J, et al.Signaling pathways in cancer-associated fibroblasts: recent advances and future perspectives[J]. Cancer Commun (Lond), 2023, 43(1): 3-41. [26] 汪玉倩, 徐可, 詹月萍, 等. 肿瘤相关成纤维细胞及其标记物的研究现状[J].中国临床药理学杂志, 2022,37(17):2094-2097. Wang YQ, Xu K, Zhan YP, et al.Research status of cancer-associated fibroblasts and their markers[J]. The Chinese Journal of Clinical Pharmacology, 2022, 37(17): 2094-2097 [27] Paulsson J, Micke P.Prognostic relevance of cancer-associated fibroblasts in human cancer[J]. Semin Cancer Biol, 2014, 25: 61-68. [28] Wen S, Hou Y, Fu L, et al.Cancer-associated fibroblast (CAF)-derived IL32 promotes breast cancer cell invasion and metastasis via integrin β3-p38 MAPK signalling[J]. Cancer Lett, 2019, 442: 320-332. [29] Desbois M, Wang Y.Cancer-associated fibroblasts: key players in shaping the tumor immune microenvironment[J]. Immunol Rev, 2021, 302(1): 241-258. [30] Vered M, Dayan D, Yahalom R, et al.Cancer-associated fibroblasts and epithelial-mesenchymal transition in metastatic oral tongue squamous cell carcinoma[J]. Int J Cancer, 2010, 127(6): 1356-1362. [31] Garaud S, Buisseret L, Solinas C, et al.Tumor infiltrating B-cells signal functional humoral immune responses in breast cancer[J]. JCI Insight, 2019, 5(18): e129641-e129660. [32] Turley SJ, Cremasco V, Astarita JL.Immunological hallmarks of stromal cells in the tumour microenvironment[J]. Nat Rev Immunol, 2015, 15(11): 669-682. [33] Thomas DA, Massagué J.TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance[J]. Cancer Cell, 2005, 8(5): 369-380. [34] Chen X, Song E.Turning foes to friends: targeting cancer-associated fibroblasts[J]. Nat Rev Drug Discov, 2019, 18(2):99-115. |